WO1994029351A3 - Antibodies - Google Patents
Antibodies Download PDFInfo
- Publication number
- WO1994029351A3 WO1994029351A3 PCT/GB1994/001290 GB9401290W WO9429351A3 WO 1994029351 A3 WO1994029351 A3 WO 1994029351A3 GB 9401290 W GB9401290 W GB 9401290W WO 9429351 A3 WO9429351 A3 WO 9429351A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- provides
- modulating
- diagnosis
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7501518A JPH08511420A (en) | 1993-06-16 | 1994-06-15 | Body |
EP94917750A EP0714409A1 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
AU69341/94A AU691811B2 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9312415.4 | 1993-06-16 | ||
GB939312415A GB9312415D0 (en) | 1993-06-16 | 1993-06-16 | Altered antibodies |
GB9401597.1 | 1994-01-27 | ||
GB9401597A GB9401597D0 (en) | 1994-01-27 | 1994-01-27 | Altered antibodies |
GB9402499A GB9402499D0 (en) | 1994-02-09 | 1994-02-09 | Altered abtibodies |
GB9402499.9 | 1994-02-09 | ||
GB9406244A GB9406244D0 (en) | 1994-03-29 | 1994-03-29 | Altered antibodies |
GB9406244.5 | 1994-03-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994029351A3 true WO1994029351A3 (en) | 1994-12-22 |
WO1994029351A2 WO1994029351A2 (en) | 1994-12-22 |
Family
ID=27451034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1994/001290 WO1994029351A2 (en) | 1993-06-16 | 1994-06-15 | Antibodies |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0714409A1 (en) |
JP (1) | JPH08511420A (en) |
AU (1) | AU691811B2 (en) |
CA (1) | CA2163345A1 (en) |
WO (1) | WO1994029351A2 (en) |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US8410250B2 (en) | 2009-03-25 | 2013-04-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US8779100B2 (en) | 2004-09-03 | 2014-07-15 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8957187B2 (en) | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
EP4342529A2 (en) | 2015-12-18 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
Families Citing this family (1086)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
ATE240395T1 (en) | 1994-03-29 | 2003-05-15 | Celltech Therapeutics Ltd | ANTIBODIES AGAINST E-SELECTIN |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
WO1999032659A1 (en) * | 1997-12-22 | 1999-07-01 | Stiftelsen Universitetsforskning Bergen (Unifob) | METHOD FOR DISEASE PROGNOSIS BASED ON Fc RECEPTOR GENOTYPING |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
CA2323757C (en) * | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
CZ20012925A3 (en) | 1999-02-12 | 2002-01-16 | Genetics Institute, Inc. | Humanized immunoglobulin reacting with B7 molecules and method of therapy |
ES2637801T3 (en) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Multivalent antibodies and uses thereof |
US7416726B2 (en) | 2000-04-13 | 2008-08-26 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
EP1881004B1 (en) | 2000-04-21 | 2012-07-25 | Fuso Pharmaceutical Industries, Ltd. | Novel collectin |
EP2251026A1 (en) | 2000-06-08 | 2010-11-17 | Immune Disease Institute, Inc. | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP2354149B1 (en) | 2000-12-12 | 2017-08-30 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
KR100968664B1 (en) | 2001-08-27 | 2010-07-06 | 제넨테크, 인크. | A System for Antibody Expression and Assembly |
EP1369431A4 (en) | 2001-10-15 | 2005-01-12 | Kirin Brewery | Anti-hla-dr antibody |
US7053202B2 (en) | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8530627B2 (en) | 2002-08-14 | 2013-09-10 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
WO2004074430A2 (en) * | 2002-12-06 | 2004-09-02 | Diadexus, Inc. | Compositions, splice variants and methods relating to lung specific genes and proteins |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
ES2340280T3 (en) | 2003-03-14 | 2010-06-01 | Wyeth Llc | DIRECTED ANTIBODIES AGAINST THE RECEIVER OF HUMAN IL-21 AND USE OF THE SAME. |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
AU2008229860B2 (en) * | 2003-05-02 | 2012-01-12 | Xencor, Inc | Optimized Fc variants and methods for their generation |
CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
DK1711207T3 (en) | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha antibodies and their use |
CN102838675B (en) | 2003-12-10 | 2014-07-30 | 梅达雷克斯有限责任公司 | Ip-10 antibodies and their uses |
JP2007521248A (en) | 2003-12-10 | 2007-08-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Humanized anti-CCR2 antibody and methods of using the antibody |
EP2275448A3 (en) | 2003-12-19 | 2013-02-06 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
JP4762156B2 (en) * | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション,インコーポレイテッド | Fc region variant |
ATE498010T1 (en) | 2004-03-01 | 2011-02-15 | Immune Disease Inst Inc | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF |
DK1737891T3 (en) * | 2004-04-13 | 2013-03-25 | Hoffmann La Roche | ANTI-P-selectin ANTIBODIES |
US7521542B2 (en) | 2004-05-10 | 2009-04-21 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
ES2526194T3 (en) | 2004-06-21 | 2015-01-08 | E. R. Squibb & Sons, L.L.C. | Interferon alfa 1 receptor antibodies, and their uses |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
ES2426817T3 (en) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Fc regions variants |
PT1773885E (en) | 2004-08-05 | 2010-07-21 | Genentech Inc | Humanized anti-cmet antagonists |
AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
JP5651285B2 (en) | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | Anti-CD19 antibodies and use in oncology |
RS59399B1 (en) | 2005-03-23 | 2019-11-29 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
ES2707152T3 (en) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Covalent diabodies and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
AU2006239851B2 (en) | 2005-04-26 | 2011-06-16 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
JP2009500344A (en) | 2005-07-01 | 2009-01-08 | メディミューン,エルエルシー | An integrated approach to manufacturing multidomain protein therapeutics |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
ES2530265T3 (en) | 2005-07-21 | 2015-02-27 | Genmab A/S | Binding potency assays of an antibody drug substance to an FC receptor |
DK2573114T3 (en) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | The identification and production of antibodies with variant Fc regions, and methods of using same |
JP2009511067A (en) | 2005-10-14 | 2009-03-19 | メディミューン,エルエルシー | Cell presentation of antibody libraries |
RU2421464C2 (en) | 2005-10-21 | 2011-06-20 | Новартис Аг | Human il-13 antibodies and their therapeutic application |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
KR101453570B1 (en) | 2005-12-02 | 2014-10-22 | 제넨테크, 인크. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
CA2638902C (en) | 2005-12-08 | 2014-09-23 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
ES2535856T3 (en) | 2005-12-15 | 2015-05-18 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
US8101365B2 (en) | 2006-01-05 | 2012-01-24 | Genentech, Inc. | Anti-EphB4 antibodies and methods using same |
RU2520088C2 (en) | 2006-01-12 | 2014-06-20 | Алексион Фармасьютикалз, Инк. | Antibodies to ox-2/cd200 and their application |
WO2007127506A2 (en) | 2006-01-20 | 2007-11-08 | Genentech, Inc. | Anti-ephrinb2 antibodies and methods using same |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
US7695928B2 (en) | 2006-04-10 | 2010-04-13 | Genentech, Inc. | Disheveled PDZ modulators |
EP2021029B1 (en) | 2006-05-26 | 2014-06-11 | MacroGenics, Inc. | Humanized fc gamma riib-specific antibodies and methods of use thereof |
WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
AU2007319672B2 (en) | 2006-06-06 | 2011-06-30 | Genentech, Inc. | Anti-DLL4 antibodies and methods using same |
ES2599319T3 (en) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Fc RIIB specific antibodies and their methods of use |
EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
ME01786B (en) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimized antibodies that target cd19 |
CN101627055A (en) | 2006-09-05 | 2010-01-13 | 梅达雷克斯公司 | The antibody of bone morphogenetic protein and acceptor thereof and their using method |
PL2066349T3 (en) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases |
SI2066351T1 (en) | 2006-10-02 | 2016-02-29 | E.R. Squibb & Sons, L.L.C. | Human antibodies that bind cxcr4 and uses thereof |
JP5238710B2 (en) | 2006-10-19 | 2013-07-17 | シーエスエル、リミテッド | High affinity antibody antagonist of interleukin-13 receptor alpha 1 |
US8613925B2 (en) | 2006-10-19 | 2013-12-24 | Csl Limited | Anti-IL-13Rα1 antibodies and their uses thereof |
PT2845866T (en) | 2006-10-27 | 2017-08-09 | Genentech Inc | Antibodies and immunoconjugates and uses therefor |
US8618248B2 (en) | 2006-10-31 | 2013-12-31 | President And Fellows Of Harvard College | Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides |
DK2087001T3 (en) | 2006-11-02 | 2017-02-06 | Acceleron Pharma Inc | ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND APPLICATIONS THEREOF |
EA200970477A1 (en) | 2006-11-15 | 2009-12-30 | Медарекс, Инк. | HUMAN MONOCLONAL ANTIBODIES TO BTLA AND METHODS OF APPLICATION |
KR20150067395A (en) | 2006-12-01 | 2015-06-17 | 메다렉스, 엘.엘.시. | Human antibodies that bind cd22 and uses thereof |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
US7834154B2 (en) | 2007-02-09 | 2010-11-16 | Genentech, Inc. | Anti-ROBO4 antibodies and uses therefor |
DK2125894T3 (en) | 2007-03-22 | 2019-03-18 | Biogen Ma Inc | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
EP2644205B1 (en) | 2007-04-12 | 2018-06-13 | The Brigham and Women's Hospital, Inc. | Targeting ABCB5 for cancer therapy |
KR20100017514A (en) | 2007-05-07 | 2010-02-16 | 메디뮨 엘엘씨 | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
PE20090321A1 (en) | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
EA200901494A1 (en) | 2007-06-06 | 2010-06-30 | Домантис Лимитед | METHODS OF SELECTION OF PROTEASO-RESISTANT POLYPEPTIDES |
EP2069401A4 (en) | 2007-07-31 | 2011-02-23 | Medimmune Llc | Multispecific epitope binding proteins and uses thereof |
JP5749009B2 (en) | 2007-08-13 | 2015-07-15 | バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. | Cancer therapeutic agent using humanized antibody binding to EphB4 |
MX2010003450A (en) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region. |
AR068767A1 (en) | 2007-10-12 | 2009-12-02 | Novartis Ag | ANTIBODIES AGAINST SCLEROSTIN, COMPOSITIONS AND METHODS OF USE OF THESE ANTIBODIES TO TREAT A PATHOLOGICAL DISORDER MEDIATIONED BY SCLEROSTIN |
PL2567709T3 (en) | 2007-11-02 | 2018-06-29 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
PT2514436T (en) | 2007-11-07 | 2018-03-21 | Genentech Inc | Il-22 for use in treating microbial disorders |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
CA3102704A1 (en) | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
EP3211010A1 (en) | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | Fc variants with altered binding to fcrn |
CA2711771C (en) | 2008-01-11 | 2017-01-24 | Gene Techno Science Co., Ltd. | Humanized anti-.alpha.9 integrin antibodies and the uses thereof |
EP2650017A3 (en) | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
KR101666229B1 (en) | 2008-02-08 | 2016-10-14 | 메디뮨 엘엘씨 | Anti-ifnar1 antibodies with reduced fc ligand affinity |
WO2009131256A1 (en) | 2008-04-24 | 2009-10-29 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof |
TWI672151B (en) | 2008-05-02 | 2019-09-21 | 艾西利羅製藥公司 | Methods and compositions for modulating angiogenesis and pericyte composition |
WO2010009271A2 (en) | 2008-07-15 | 2010-01-21 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
US9182406B2 (en) | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
SG10201405377XA (en) | 2008-08-05 | 2014-12-30 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
KR20110057244A (en) | 2008-09-19 | 2011-05-31 | 메디뮨 엘엘씨 | Antibodies directed to dll4 and uses thereof |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
AU2009324037B2 (en) | 2008-12-05 | 2015-07-30 | Glaxo Group Limited | Methods for selecting protease resistant polypeptides |
CA2745492A1 (en) | 2008-12-08 | 2010-06-17 | Compugen Ltd. | A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
MX2011008799A (en) | 2009-02-19 | 2011-09-27 | Glaxo Group Ltd | Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists. |
AU2010215239A1 (en) | 2009-02-23 | 2011-09-15 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
PT2403878T (en) | 2009-03-05 | 2017-09-01 | Squibb & Sons Llc | Fully human antibodies specific to cadm1 |
TWI461211B (en) | 2009-03-20 | 2014-11-21 | Genentech Inc | Anti-her antibodies |
SG10201609416XA (en) | 2009-03-25 | 2016-12-29 | Genentech Inc | NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF |
KR20120057563A (en) | 2009-03-31 | 2012-06-05 | 노파르티스 아게 | Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit |
NZ595792A (en) | 2009-04-20 | 2014-01-31 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17 |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
HUE035240T2 (en) | 2009-04-27 | 2018-05-02 | Novartis Ag | Compositions and methods for increasing muscle growth |
TWI614267B (en) | 2009-05-13 | 2018-02-11 | 建新公司 | Anti-human cd52 immunoglobulins |
DK2995315T3 (en) | 2009-05-15 | 2024-02-19 | Univ Health Network | Compositions and methods for treating hematological cancers targeting interaction between Sirp alpha and CD47 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
CA2765989C (en) | 2009-06-18 | 2016-11-29 | Pfizer Inc. | Anti notch-1 antibodies |
WO2011051217A1 (en) | 2009-10-27 | 2011-05-05 | Glaxo Group Limited | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists |
WO2011006914A2 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
EP3199551A3 (en) | 2009-07-31 | 2017-10-18 | E. R. Squibb & Sons, L.L.C. | Fully human antibodies to btla |
WO2011021146A1 (en) | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Osteopontin antibodies |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
JP5889794B2 (en) | 2009-10-19 | 2016-03-22 | ジェネンテック, インコーポレイテッド | Regulation of hepatocyte growth factor activator |
JP5814925B2 (en) | 2009-10-22 | 2015-11-17 | ジェネンテック, インコーポレイテッド | Anti-hepsin antibody and method of use thereof |
CN110054692A (en) | 2009-10-23 | 2019-07-26 | 米伦纽姆医药公司 | Anti- GCC antibody molecule and its compositions related and method |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
JO3437B1 (en) * | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | Improved anti human Fraktalkine antibodies and uses thereof |
CA2779384C (en) | 2009-11-04 | 2018-02-27 | Schering Corporation | Engineered anti-tslp antibody |
RU2585488C2 (en) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Methods and composition for secretion of heterologous polypeptides |
HUE037159T2 (en) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targeted binding agents against b7-h1 |
US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
RU2012127383A (en) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF FC-FILLED PROTEINS IN SERUM |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
KR20120107122A (en) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | Tetravalent cd47-antibody constant region fusion protein for use in therapy |
HUE028629T2 (en) * | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
KR20130005264A (en) | 2010-01-11 | 2013-01-15 | 알렉시온 파마슈티칼스, 인코포레이티드 | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
JP5841072B2 (en) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | CD20 antibody and use thereof |
CN102770767A (en) | 2010-02-10 | 2012-11-07 | 诺瓦提斯公司 | Methods and compounds for muscle growth |
US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
US9556249B2 (en) | 2010-02-18 | 2017-01-31 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
KR20230044026A (en) | 2010-02-24 | 2023-03-31 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
NZ602040A (en) | 2010-03-24 | 2014-12-24 | Genentech Inc | Anti-lrp6 antibodies |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
CA3079122A1 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
AU2011249782B2 (en) | 2010-05-06 | 2014-10-02 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies |
ES2659406T3 (en) | 2010-05-06 | 2018-03-15 | Novartis Ag | Compositions and methods of use for therapeutic antibodies against protein 6 related to low density lipoproteins (LRP6) |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
BR112012027995A2 (en) | 2010-06-18 | 2017-01-10 | Genentech Inc | antibody and isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating an individual with cancer, an individual having an immune disorder, inhibiting angiogenesis and inhibiting the constitutive activation of axl |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
MX2013000083A (en) | 2010-07-09 | 2013-02-26 | Genentech Inc | Anti-neuropilin antibodies and methods of use. |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
CN103154025B (en) | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
MX2013001302A (en) | 2010-08-03 | 2013-03-08 | Hoffmann La Roche | Chronic lymphocytic leukemia (cll) biomarkers. |
EP2600898A1 (en) | 2010-08-05 | 2013-06-12 | F.Hoffmann-La Roche Ag | Anti-mhc antibody anti-viral cytokine fusion protein |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
JP5841149B2 (en) | 2010-08-13 | 2016-01-13 | ロシュ グリクアート アーゲー | Anti-tenascin CA2 antibody and method of use |
MY175341A (en) | 2010-08-13 | 2020-06-19 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
CN103080134B (en) | 2010-08-20 | 2015-11-25 | 诺华股份有限公司 | The antibody of EGF-R ELISA 3 (HER3) |
TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
DK2612151T3 (en) | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
EP2616100B1 (en) | 2010-09-17 | 2016-08-31 | Compugen Ltd. | Compositions and methods for treatment of drug resistant multiple myeloma |
EP2625203A1 (en) | 2010-10-05 | 2013-08-14 | Novartis AG | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US8772457B2 (en) | 2010-11-10 | 2014-07-08 | Genentech, Inc. | BACE1 antibodies |
US10208129B2 (en) | 2010-12-06 | 2019-02-19 | National Research Council Of Canada | Antibodies selective for cells presenting ErbB2 at high density |
JP6016800B2 (en) | 2010-12-15 | 2016-10-26 | ワイス・エルエルシー | Anti-notch1 antibody |
JP6005657B2 (en) | 2010-12-16 | 2016-10-12 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment related to TH2 inhibition |
MX345519B (en) | 2010-12-20 | 2017-02-01 | Genentech Inc | Anti-mesothelin antibodies and immunoconjugates. |
CA2820953A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
CA2825255C (en) | 2011-01-24 | 2021-05-18 | Ym Biosciences Inc. | Antibodies selective for cells presenting egfr at high density |
AU2012212066A1 (en) | 2011-02-03 | 2013-08-15 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
KR101638224B1 (en) | 2011-02-28 | 2016-07-08 | 에프. 호프만-라 로슈 아게 | Antigen binding proteins |
JP5768147B2 (en) | 2011-02-28 | 2015-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Monovalent antigen binding protein |
CA2831136A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
ES2661466T3 (en) | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Methods to increase the effectiveness of cancer therapy with FOLR1 |
EP2694551A1 (en) | 2011-04-07 | 2014-02-12 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
PT2697257T (en) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
EP2697256A1 (en) | 2011-04-15 | 2014-02-19 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
CN108341863A (en) | 2011-04-20 | 2018-07-31 | 阿塞勒隆制药公司 | Endoglin polypeptide and application thereof |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
UA116189C2 (en) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
CN108969469A (en) | 2011-05-02 | 2018-12-11 | 米伦纽姆医药公司 | The preparation of 4 β of anti alpha, 7 antibody |
CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
PL2707391T3 (en) | 2011-05-13 | 2018-04-30 | Gamamabs Pharma | Antibodies against her3 |
RS56090B1 (en) | 2011-05-16 | 2017-10-31 | Hoffmann La Roche | Fgfr1 agonists and methods of use |
MX347818B (en) | 2011-05-21 | 2017-05-15 | Macrogenics Inc | Deimmunized serum-binding domains and their use for extending serum half-life. |
ES2704038T3 (en) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Multivalent and monovalent multispecific complexes and their uses |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
EP2721067B1 (en) | 2011-06-15 | 2019-07-31 | F.Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
CA2838478A1 (en) | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
EP2723376B1 (en) | 2011-06-22 | 2018-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
BR112013032899A2 (en) | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anti-axl antibodies and uses thereof |
CN110229235A (en) | 2011-06-22 | 2019-09-13 | 霍夫曼-拉罗奇有限公司 | Target cell is removed by the HIV-specific cytotoxic T lymphocytes in circulation using the compound comprising MHC I class |
CA2840537C (en) | 2011-06-28 | 2021-12-14 | Oxford Biotherapeutics Ltd. | Antibodies to adp-ribosyl cyclase 2 |
CN107090038A (en) | 2011-06-30 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | Anti- C MET antibody formulations |
SI2726099T1 (en) | 2011-07-01 | 2018-11-30 | Novartis Ag | Method for treating metabolic disorders |
CA3158257A1 (en) | 2011-07-11 | 2013-01-17 | Ichnos Sciences SA | Antibodies that bind to ox40 and their uses |
JP2014526886A (en) | 2011-07-15 | 2014-10-09 | モルフォシス・アー・ゲー | Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT) |
EP2744824A1 (en) | 2011-08-17 | 2014-06-25 | F.Hoffmann-La Roche Ag | Neuregulin antibodies and uses thereof |
US9309306B2 (en) | 2011-08-23 | 2016-04-12 | Roche Glycart Ag | Anti-MCSP antibodies |
WO2013040433A1 (en) | 2011-09-15 | 2013-03-21 | Genentech, Inc. | Methods of promoting differentiation |
CA2846630A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
KR102017070B1 (en) | 2011-09-30 | 2019-09-02 | 다나-파버 캔서 인스티튜트 인크. | Therapeutic peptides |
MX2014004074A (en) | 2011-10-05 | 2014-06-05 | Genentech Inc | Methods of treating liver conditions using notch2 antagonists. |
CN104080471B (en) | 2011-10-14 | 2018-08-10 | 诺华股份有限公司 | Antibody and method for Wnt approach relevant diseases |
KR102102862B1 (en) | 2011-10-14 | 2020-04-22 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
JP6190813B2 (en) | 2011-10-14 | 2017-08-30 | ジェネンテック, インコーポレイテッド | Zymogen activator |
US9358250B2 (en) | 2011-10-15 | 2016-06-07 | Genentech, Inc. | Methods of using SCD1 antagonists |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
KR20140097205A (en) | 2011-10-28 | 2014-08-06 | 제넨테크, 인크. | Therapeutic combinations and methods of treating melanoma |
CN103906533A (en) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | Multispecific and multivalent binding proteins and uses thereof |
BR112014012005A2 (en) | 2011-11-21 | 2017-12-19 | Genentech Inc | compositions, methods, pharmaceutical formulation and article |
JP6243345B2 (en) | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | Antibody to epidermal growth factor receptor 3 (HER3) |
KR20140103135A (en) | 2011-12-05 | 2014-08-25 | 노파르티스 아게 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
RU2685867C2 (en) | 2011-12-15 | 2019-04-23 | Алтернатив Инновейтив Текнолоджиз Ллц | Hybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions) |
CN106831985A (en) | 2011-12-21 | 2017-06-13 | 诺华股份有限公司 | The composition and method of the P factors are targeted for antibody |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
IN2014DN05885A (en) | 2012-01-18 | 2015-06-05 | Hoffmann La Roche | |
EP2804630B1 (en) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Methods of using fgf19 modulators |
MX2014009289A (en) | 2012-02-01 | 2015-09-08 | Compugen Ltd | C10rf32 antibodies, and uses thereof for treatment of cancer. |
KR102148303B1 (en) | 2012-02-11 | 2020-08-26 | 제넨테크, 인크. | R-spondin translocations and methods using the same |
RU2624128C2 (en) | 2012-02-15 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
RU2014141617A (en) | 2012-03-16 | 2016-05-10 | Дженентек, Инк. | DESIGNED CONFORMATION-STABILIZED PROTEINS |
EP2831115A1 (en) | 2012-03-27 | 2015-02-04 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to her3 inhibitors |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
AU2013243861A1 (en) | 2012-04-05 | 2014-10-23 | Ac Immune S.A. | Humanized Tau antibody |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
GB2517857A (en) | 2012-04-25 | 2015-03-04 | Biodesy Inc | Methods for detecting allosteric modulators of proteins |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
AR090903A1 (en) | 2012-05-01 | 2014-12-17 | Genentech Inc | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
RU2625771C2 (en) | 2012-05-23 | 2017-07-18 | Дженентек, Инк. | Therapeutics selection method |
US9585970B2 (en) | 2012-06-04 | 2017-03-07 | Novartis Ag | Site-specific labeling methods and molecules produced thereby |
WO2013183032A2 (en) | 2012-06-08 | 2013-12-12 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
ES2600154T3 (en) | 2012-07-04 | 2017-02-07 | F. Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
CN104411725B (en) | 2012-07-04 | 2018-09-28 | 弗·哈夫曼-拉罗切有限公司 | Anti-biotin antibodies and application method |
KR102090849B1 (en) | 2012-07-04 | 2020-03-19 | 에프. 호프만-라 로슈 아게 | Covalently linked antigen-antibody conjugates |
MX356162B (en) | 2012-07-05 | 2018-05-16 | Genentech Inc | Expression and secretion system. |
SG11201500096YA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti - cd79b antibodies |
TW201406785A (en) | 2012-07-09 | 2014-02-16 | Genentech Inc | Anti-CD22 antibodies and immunoconjugates |
SG11201500093TA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd79b antibodies |
EP2869851A1 (en) | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
HRP20211641T1 (en) | 2012-07-13 | 2022-02-04 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
SI2880170T1 (en) | 2012-08-02 | 2016-12-30 | F. Hoffmann-La Roche Ag | METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF |
JP6302909B2 (en) | 2012-08-18 | 2018-03-28 | アカデミア シニカAcademia Sinica | Cell-permeable probes for sialidase identification and imaging |
HUE049693T2 (en) | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
JP6368308B2 (en) | 2012-09-07 | 2018-08-01 | トラスティーズ・オブ・ダートマス・カレッジ | VISTA modulators for cancer diagnosis and treatment |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
PE20150956A1 (en) | 2012-11-08 | 2015-06-20 | Hoffmann La Roche | HER3 FORK BINDING HER3 ANTIGEN BINDING PROTEINS |
WO2014078268A2 (en) | 2012-11-13 | 2014-05-22 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
CN104968678B (en) | 2012-12-05 | 2018-12-11 | 诺华股份有限公司 | Target the composition and method of the antibody of EPO |
EA034757B1 (en) | 2012-12-10 | 2020-03-17 | Байоджен Ма Инк. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
SI3575326T1 (en) | 2012-12-17 | 2022-08-31 | Pf Argentum Ip Holdings Llc | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
KR20150097688A (en) | 2012-12-21 | 2015-08-26 | 에프. 호프만-라 로슈 아게 | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
MY173334A (en) | 2013-01-02 | 2020-01-16 | Ichnos Sciences SA | Antibodies that bind to tl1a and their uses |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
AU2014214751B2 (en) | 2013-02-08 | 2017-06-01 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
PL2953969T3 (en) | 2013-02-08 | 2020-02-28 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
WO2015198217A2 (en) | 2013-02-08 | 2015-12-30 | Novartis Ag | Compositions and methods for long-acting antibodies targeting il-17 |
EP3299378B1 (en) | 2013-02-12 | 2019-07-31 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
JP2016509045A (en) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | How to treat cancer and prevent drug resistance |
KR20150123811A (en) | 2013-02-26 | 2015-11-04 | 로슈 글리카트 아게 | Anti-mcsp antibodies |
JP2016510751A (en) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | Methods of treating and preventing anticancer drug resistance |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
CN105189552B (en) | 2013-03-14 | 2019-08-02 | 基因泰克公司 | Anti- B7-H4 antibody and immunoconjugates |
SG11201507477XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
EP2970479B1 (en) | 2013-03-14 | 2019-04-24 | Novartis AG | Antibodies against notch 3 |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
EP2968565A2 (en) | 2013-03-14 | 2016-01-20 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
MX2015011899A (en) | 2013-03-15 | 2016-05-05 | Genentech Inc | Methods of treating cancer and preventing cancer drug resistance. |
SG10201808523RA (en) | 2013-03-15 | 2018-11-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
CN105392801A (en) | 2013-03-15 | 2016-03-09 | 比奥根Ma公司 | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
CN105142668B (en) | 2013-03-15 | 2018-04-27 | 达纳-法伯癌症研究院公司 | Therapeutic peptide |
BR112015023752B1 (en) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX |
CN105007950B (en) | 2013-03-15 | 2019-01-15 | 诺华股份有限公司 | Antibody drug conjugate |
CN105143264A (en) | 2013-03-15 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Compositions and methods for diagnosis and treatment of hepatic cancers |
MY197809A (en) | 2013-03-15 | 2023-07-18 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
AR095199A1 (en) | 2013-03-15 | 2015-09-30 | Genzyme Corp | ANTI-CD52 ANTIBODIES |
EP2970471A2 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Anti-crth2 antibodies and their use |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
US9598485B2 (en) | 2013-03-15 | 2017-03-21 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
CN105164158A (en) | 2013-04-29 | 2015-12-16 | 豪夫迈·罗氏有限公司 | Fcrn-binding abolished ANTI-IGF-1R antibodies and their use in the treatment of vascular eye diseases |
RU2019108429A (en) | 2013-04-29 | 2019-05-06 | Ф. Хоффманн-Ля Рош Аг | MODIFIED ASYMMETRIC ANTIBODIES CONNECTING FC-RECEPTOR AND METHODS OF THEIR APPLICATION |
ES2746136T3 (en) | 2013-04-29 | 2020-03-04 | Hoffmann La Roche | Modified Human FcRn Binding Antibodies and Methods of Use |
AR096364A1 (en) | 2013-05-20 | 2015-12-23 | Genentech Inc | ANTITRANSPHERINE RECEIVING ANTIBODIES AND METHODS OF USE |
US10053510B2 (en) | 2013-05-24 | 2018-08-21 | Promis Neurosciences Inc. | FasR antibodies and methods of use |
US9562101B2 (en) | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
AR096601A1 (en) | 2013-06-21 | 2016-01-20 | Novartis Ag | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
CN105814074B (en) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | Humanized antibodies with ultralong complementarity determining regions |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
TW201536318A (en) | 2013-08-14 | 2015-10-01 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
HUE055856T2 (en) | 2013-08-30 | 2021-12-28 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
CA2923579C (en) | 2013-09-06 | 2023-09-05 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
CN112552401B (en) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | anti-PD 1 antibodies and their use as therapeutic and diagnostic agents |
JP2016537399A (en) | 2013-09-17 | 2016-12-01 | ジェネンテック, インコーポレイテッド | Method using anti-LGR5 antibody |
JP6534615B2 (en) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
US10494419B2 (en) | 2013-10-02 | 2019-12-03 | Medimmune, Llc | Neutralizing anti-influenza A antibodies and uses thereof |
EP3055328A1 (en) | 2013-10-11 | 2016-08-17 | F. Hoffmann-La Roche AG | Nsp4 inhibitors and methods of use |
MX2016003593A (en) | 2013-10-11 | 2016-06-02 | Hoffmann La Roche | Multispecific domain exchanged common variable light chain antibodies. |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
EP3057615B1 (en) | 2013-10-18 | 2021-02-24 | F.Hoffmann-La Roche Ag | Anti-rspo antibodies and methods of use |
EP3060685B1 (en) | 2013-10-23 | 2019-05-01 | F. Hoffmann-La Roche AG | Method of predicting the response of an asthma patient to therapy |
CA2928708A1 (en) | 2013-10-25 | 2015-04-30 | Acceleron Pharma, Inc. | Endoglin peptides to treat fibrotic diseases |
JP6449876B2 (en) | 2013-11-07 | 2019-01-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Anti-human HER3 antibody that is non-competitive and allosteric for neuregulin and uses thereof |
CN104623637A (en) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Application of IL-22 dimer in preparation of intravenous injection drugs |
SG10202007189VA (en) | 2013-11-21 | 2020-09-29 | Hoffmann La Roche | ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE |
MX371187B (en) | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Therapeutic peptides. |
AU2014363944B2 (en) | 2013-12-09 | 2020-03-26 | Allakos Inc. | Anti-Siglec-8 antibodies and methods of use thereof |
TW201533060A (en) | 2013-12-13 | 2015-09-01 | Genentech Inc | Anti-CD33 antibodies and immunoconjugates |
PT3083686T (en) | 2013-12-17 | 2019-12-18 | Hoffmann La Roche | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
EP3083687A2 (en) | 2013-12-17 | 2016-10-26 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
AU2014364593A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and an anti-CD20 antibody |
RS60443B1 (en) | 2013-12-17 | 2020-07-31 | Genentech Inc | Anti-cd3 antibodies and methods of use |
EP3083680B1 (en) | 2013-12-20 | 2020-01-15 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
TWI728373B (en) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | Antibodies and methods of use |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
SI3712174T1 (en) | 2013-12-24 | 2022-06-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
JP6554473B2 (en) | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | FcRn antagonists and methods of use |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
WO2015101587A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
EP3851452A1 (en) | 2014-01-06 | 2021-07-21 | F. Hoffmann-La Roche AG | Monovalent blood brain barrier shuttle modules |
CN110903398B (en) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | Fc region variants with modified FCRN and maintained protein A binding properties |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
RU2016130349A (en) | 2014-01-24 | 2018-03-01 | Дженентек, Инк. | WAYS OF APPLICATION OF ANTIBODIES AGAINST STEAP1 AND IMMUNOCONJUGATES |
CA2937539A1 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
BR112016018205A8 (en) | 2014-02-08 | 2018-04-17 | Genentech Inc | methods of treating alzheimer's disease, patient selection, patient identification, prediction, therapeutic efficacy optimization, kit, agent use and in vitro agent use |
KR20160111039A (en) | 2014-02-08 | 2016-09-23 | 제넨테크, 인크. | Methods of treating alzheimer's disease |
TR201810635T4 (en) | 2014-02-12 | 2018-08-27 | Hoffmann La Roche | Anti-jagged1 antibodies and methods of use. |
EP3107574A2 (en) | 2014-02-21 | 2016-12-28 | F. Hoffmann-La Roche AG | Anti-il-13/il-17 bispecific antibodies and uses thereof |
DK3110446T3 (en) | 2014-02-28 | 2022-02-28 | Allakos Inc | Methods and compositions for treating Siglec-8-associated diseases |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
BR112016020065A2 (en) | 2014-03-12 | 2018-02-20 | Novartis Ag | specific sites to modify antibodies to make immunoconjugates |
RU2748026C2 (en) | 2014-03-14 | 2021-05-19 | Дженентек, Инк. | Methods and compositions for secretion of heterologous polypeptides |
EP3925973A1 (en) | 2014-03-14 | 2021-12-22 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
BR112016021383A2 (en) | 2014-03-24 | 2017-10-03 | Genentech Inc | METHOD TO IDENTIFY A PATIENT WITH CANCER WHO IS LIKE OR LESS LIKELY TO RESPOND TO TREATMENT WITH A CMET ANTAGONIST, METHOD TO IDENTIFY A PATIENT WITH PREVIOUSLY TREATED CANCER, METHOD TO DETERMINE THE EXPRESSION OF THE HGF BIOMARKER, ANTI-C-MET ANTAGONIST AND ITS USE, DIAGNOSTIC KIT AND ITS PREPARATION METHOD |
CN106415244B (en) | 2014-03-27 | 2020-04-24 | 中央研究院 | Reactive marker compounds and uses thereof |
JP6588461B2 (en) | 2014-03-31 | 2019-10-09 | ジェネンテック, インコーポレイテッド | Combination therapy comprising an anti-angiogenic agent and an OX40 binding agonist |
DK3126394T3 (en) | 2014-03-31 | 2020-01-13 | Hoffmann La Roche | Anti-OX40 antibodies and methods of use |
EP3134439B1 (en) | 2014-04-21 | 2018-12-26 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
MX2016014504A (en) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Humanized c5 and c3 animals. |
CN106414499A (en) | 2014-05-22 | 2017-02-15 | 基因泰克公司 | Anti-GPC3 antibodies and immunoconjugates |
JP2017524371A (en) | 2014-05-23 | 2017-08-31 | ジェネンテック, インコーポレイテッド | MIT biomarkers and methods of use |
EP4116329A1 (en) | 2014-05-27 | 2023-01-11 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
TWI717319B (en) | 2014-05-27 | 2021-02-01 | 中央研究院 | Fucosidase from bacteroides and methods using the same |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
MX2016016233A (en) | 2014-06-11 | 2017-03-31 | Genentech Inc | Anti-lgr5 antibodies and uses thereof. |
WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
CN107073121A (en) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | Treatment and the method for prevention cancer drug resistance |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
MX2016015280A (en) | 2014-06-26 | 2017-03-03 | Hoffmann La Roche | Anti-brdu antibodies and methods of use. |
CN110156892B (en) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | anti-PD-L1 antibodies and their use as therapeutic and diagnostic agents |
BR112017000497B1 (en) | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | ISOLATED ANTIBODY, PROKARYOTIC HOST CELL, IMMUNOCONJUGATE AND METHOD FOR DETECTING THE PRESENCE OR LEVEL OF PD-L1 EXPRESSION |
US9914774B2 (en) | 2014-07-11 | 2018-03-13 | Genentech, Inc. | Notch pathway inhibition |
AU2015292678B2 (en) | 2014-07-22 | 2020-10-22 | Cb Therapeutics, Inc. | Anti-PD-1 antibodies |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
US10435470B2 (en) | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
JP6649358B2 (en) | 2014-08-07 | 2020-02-19 | ノバルティス アーゲー | Angiopoietin-like 4 antibodies and methods of use |
PE20170903A1 (en) | 2014-08-12 | 2017-07-12 | Novartis Ag | DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES |
AP2017009765A0 (en) | 2014-08-19 | 2017-02-28 | Merck Sharp & Dohme | Anti-tigit antibodies |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
CN107074975A (en) | 2014-08-28 | 2017-08-18 | 生物蛋白有限公司 | Condition active chimeric antigen receptor for the T cell of modification |
CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
EP3191521A2 (en) | 2014-09-12 | 2017-07-19 | F. Hoffmann-La Roche AG | Cysteine engineered antibodies and conjugates |
ES2830385T3 (en) | 2014-09-12 | 2021-06-03 | Genentech Inc | Anti-HER2 antibodies and immunoconjugates |
CN113698488A (en) | 2014-09-12 | 2021-11-26 | 基因泰克公司 | anti-B7-H4 antibodies and immunoconjugates |
TW201625690A (en) | 2014-09-12 | 2016-07-16 | 建南德克公司 | Anti-CLL-1 antibodies and immunoconjugates |
BR112017004953A2 (en) | 2014-09-17 | 2017-12-05 | Genentech Inc | immunoconjugate, pharmaceutical formulation, method of treatment and method of inhibiting cell proliferation |
ES2796903T3 (en) | 2014-09-23 | 2020-11-30 | Hoffmann La Roche | Procedure for the use of anti-CD79b immunoconjugates |
SG11201702544WA (en) | 2014-09-29 | 2017-04-27 | Univ Duke | Bispecific molecules comprising an hiv-1 envelope targeting arm |
MA41044A (en) | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
JP2017536102A (en) | 2014-10-16 | 2017-12-07 | ジェネンテック, インコーポレイテッド | Anti-alpha-synuclein antibodies and methods of use |
MA41480A (en) | 2014-10-17 | 2017-12-19 | Glenmark Pharmaceuticals Sa | ANTIBODIES BOUND TO CCR6 AND THEIR USES |
CN106796235B (en) | 2014-11-03 | 2021-01-29 | 豪夫迈·罗氏有限公司 | Assays for detecting T cell immune subsets and methods of use thereof |
AU2015343339A1 (en) | 2014-11-03 | 2017-06-15 | Genentech, Inc. | Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment |
BR112017008666A2 (en) | 2014-11-05 | 2018-01-30 | Genentech, Inc. | anti-fgfr2 / 3 antibodies and methods of use |
JP6875276B2 (en) | 2014-11-05 | 2021-05-19 | ジェネンテック, インコーポレイテッド | Method of producing double-stranded protein in bacteria |
AU2015342964B2 (en) | 2014-11-05 | 2021-06-24 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
MX2017005150A (en) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Fc-region variants with modified fcrn- and protein a-binding properties. |
MX2017005148A (en) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Fc-region variants with modified fcrn-binding and methods of use. |
JP2017534633A (en) | 2014-11-06 | 2017-11-24 | ジェネンテック, インコーポレイテッド | Combination therapy comprising an OX40 binding agonist and a TIGIT inhibitor |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
CN107172879B (en) | 2014-11-10 | 2021-11-05 | 豪夫迈·罗氏有限公司 | Anti-interleukin-33 antibodies and uses thereof |
WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
EP3221360A1 (en) | 2014-11-17 | 2017-09-27 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
JP6779876B2 (en) | 2014-11-19 | 2020-11-04 | ジェネンテック, インコーポレイテッド | Anti-transferrin receptor antibody and how to use it |
CN107250158B (en) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use |
CN107108745B (en) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | Antibodies against BACE1 and their use for immunotherapy of neurological diseases |
MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
CA2968382A1 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
JP2017537105A (en) | 2014-11-26 | 2017-12-14 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Bedolizumab for the treatment of Crohn's disease with fistula |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
MY188799A (en) | 2014-12-05 | 2022-01-04 | Genentech Inc | Anti-cd79b antibodies and methods of use |
JP6864953B2 (en) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Human monoclonal antibody against AXL |
BR112017011234A2 (en) | 2014-12-10 | 2018-03-27 | Genentech Inc | antibodies to the blood-brain barrier receptor and methods of use |
EP3233921B1 (en) | 2014-12-19 | 2021-09-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
UY36449A (en) | 2014-12-19 | 2016-07-29 | Novartis Ag | COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6 |
PT3233912T (en) | 2014-12-19 | 2021-08-09 | Regenesance B V | Antibodies that bind human c6 and uses thereof |
EP3237906B8 (en) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
KR102644115B1 (en) | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies to tigit |
CN107530423B (en) | 2015-01-14 | 2022-04-05 | 布里格姆及妇女医院股份有限公司 | Treatment of cancer with anti-LAP monoclonal antibodies |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
WO2016117346A1 (en) | 2015-01-22 | 2016-07-28 | Chugai Seiyaku Kabushiki Kaisha | A combination of two or more anti-c5 antibodies and methods of use |
CA2972072A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
TWI710571B (en) | 2015-01-24 | 2020-11-21 | 中央研究院 | Cancer markers and methods of use thereof |
CN114773470A (en) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof |
HUE049791T2 (en) | 2015-02-19 | 2020-10-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
MA41636A (en) | 2015-03-06 | 2018-01-09 | Millennium Pharm Inc | METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS |
CA2978253A1 (en) | 2015-03-09 | 2016-09-15 | Argenx Bvba | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
AU2016233398A1 (en) | 2015-03-16 | 2017-09-07 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
RU2021124437A (en) | 2015-04-03 | 2021-09-29 | Еурека Терапьютикс, Инк. | CONSTRUCTIONS AIMED AT THE AFP / MHC PEPTIDE COMPLEXES AND THEIR USES |
JP2018512856A (en) | 2015-04-17 | 2018-05-24 | アルパイン イミューン サイエンシズ インコーポレイテッド | Immunomodulating proteins with tunable affinity |
PL3286315T3 (en) | 2015-04-24 | 2021-11-02 | F. Hoffmann-La Roche Ag | Methods of identifying bacteria comprising binding polypeptides |
EP3778640A1 (en) | 2015-05-01 | 2021-02-17 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
US10259882B2 (en) | 2015-05-07 | 2019-04-16 | Agenus Inc. | Anti-OX40 antibodies |
WO2016183104A1 (en) | 2015-05-11 | 2016-11-17 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
MX2017014381A (en) | 2015-05-12 | 2018-03-02 | Genentech Inc | Therapeutic and diagnostic methods for cancer. |
EP3298044B1 (en) | 2015-05-22 | 2021-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor |
JP6797137B2 (en) | 2015-05-29 | 2020-12-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Antibodies to OX40 and its use |
PL3303632T5 (en) | 2015-05-29 | 2023-07-03 | F. Hoffmann-La Roche Ag | Therapeutic and diagnostic methods for cancer |
EP3302563A1 (en) | 2015-05-29 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
CN107849124B (en) | 2015-06-05 | 2021-09-24 | 基因泰克公司 | anti-TAU antibodies and methods of use |
AU2016273028B2 (en) | 2015-06-05 | 2019-02-14 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
UA124615C2 (en) | 2015-06-16 | 2021-10-20 | Дженентек, Інк. | Humanized and affinity matured antibodies to fcrh5 and methods of use |
AU2016280159A1 (en) | 2015-06-17 | 2017-12-07 | Genentech, Inc. | Anti-HER2 antibodies and methods of use |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
WO2016205567A1 (en) | 2015-06-17 | 2016-12-22 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
CA2990360C (en) | 2015-06-24 | 2024-02-13 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
RS62986B1 (en) | 2015-06-24 | 2022-03-31 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
US9862763B2 (en) | 2015-06-24 | 2018-01-09 | Hoffmann-La Roche Inc. | Humanized anti-tau(pS422) antibodies and methods of use |
JOP20200312A1 (en) | 2015-06-26 | 2017-06-16 | Novartis Ag | Factor xi antibodies and methods of use |
JP2018520153A (en) | 2015-06-29 | 2018-07-26 | ジェネンテック, インコーポレイテッド | Type II anti-CD20 antibody for use in organ transplantation |
ES2878316T3 (en) | 2015-06-29 | 2021-11-18 | Ventana Med Syst Inc | Materials and Procedures for Histochemical Assays for Human Pro-epiregulin and Ampheregulin |
AU2016291846B2 (en) | 2015-07-13 | 2022-05-26 | Compugen Ltd. | HIDE1 Compositions and Methods |
US11236159B2 (en) | 2015-08-03 | 2022-02-01 | Novartis Ag | Methods of treating FGF21-associated disorders |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
WO2017040342A1 (en) | 2015-08-28 | 2017-03-09 | Genentech, Inc. | Anti-hypusine antibodies and uses thereof |
BR112018003186A2 (en) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anti-pd-1 antibodies and their methods of use |
US10000561B2 (en) | 2015-09-09 | 2018-06-19 | Novartis Ag | Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules |
CA2996635A1 (en) | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
JP6880006B2 (en) | 2015-09-17 | 2021-06-02 | イミュノジェン, インコーポレイテッド | A therapeutic combination that includes an anti-FOLR1 immune complex |
MX2018003005A (en) | 2015-09-18 | 2018-04-11 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof. |
JP6904947B2 (en) | 2015-09-22 | 2021-07-21 | スプリング バイオサイエンス コーポレーション | Anti-OX40 antibody and its diagnostic applications |
RU2763916C2 (en) | 2015-09-23 | 2022-01-11 | Дженентек, Инк. | Optimized options of anti-vegf antibodies |
EP3662930A1 (en) | 2015-09-24 | 2020-06-10 | AbVitro LLC | Hiv antibody compositions and methods of use |
AR106188A1 (en) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE |
PL3356404T3 (en) | 2015-10-02 | 2022-01-03 | F. Hoffmann-La Roche Ag | Anti-pd1 antibodies and methods of use |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
BR112018002570A2 (en) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | bispecific antigen binding molecule, bispecific antibody, polynucleotides, ox40-specific binding antibody, pharmaceutical composition and method for inhibiting tumor cell growth in an individual |
AR106189A1 (en) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
TWI747843B (en) | 2015-10-02 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
SI3356411T1 (en) | 2015-10-02 | 2021-09-30 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
CN108271377B (en) | 2015-10-07 | 2021-11-19 | 豪夫迈·罗氏有限公司 | Bispecific antibodies having a tetravalent targeting co-stimulatory TNF receptor |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
EP3368568B1 (en) | 2015-10-29 | 2022-04-06 | F. Hoffmann-La Roche AG | Anti-variant fc-region antibodies and methods of use |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
IL295097A (en) | 2015-10-30 | 2022-09-01 | Genentech Inc | Anti-htra1 antibodies and methods of use thereof |
CN108289951A (en) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
JP6998869B2 (en) | 2015-11-08 | 2022-02-04 | ジェネンテック, インコーポレイテッド | Screening method for multispecific antibody |
EA201891121A1 (en) | 2015-11-19 | 2018-12-28 | Бристол-Майерс Сквибб Компани | ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS |
EP3383903A1 (en) | 2015-11-30 | 2018-10-10 | Bristol-Myers Squibb Company | Anti human ip-10 antibodies and their uses |
US11447557B2 (en) | 2015-12-02 | 2022-09-20 | Agenus Inc. | Antibodies and methods of use thereof |
UY37003A (en) | 2015-12-04 | 2017-06-30 | Novartis Ag | COMPOSITIONS OF ANTIBODY INTEGRATED WITH CYTOQUINE AND METHODS FOR USE IN IMMUNOR REGULATION |
BR112018012352A2 (en) | 2015-12-16 | 2018-12-11 | Merck Sharp & Dohme Corp. | anti-lag3 antibodies and antigen binding fragments |
JP2019506844A (en) | 2015-12-18 | 2019-03-14 | ノバルティス アーゲー | Antibodies targeting CD32b and methods of use thereof |
CA3048202A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by inhibition of nonsense mediated decay |
IL259588B2 (en) | 2016-01-08 | 2023-09-01 | Hoffmann La Roche | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CN108602883A (en) | 2016-01-20 | 2018-09-28 | 基因泰克公司 | High-dose therapy for Alzheimer's disease |
JP2019509721A (en) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | Mutant smoothened and method of using the same |
JP2019509993A (en) | 2016-02-12 | 2019-04-11 | ヤンセン ファーマシューティカ エヌブイ | Anti-VISTA (B7H5) antibody |
WO2017151502A1 (en) | 2016-02-29 | 2017-09-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
US20200002422A1 (en) | 2016-03-14 | 2020-01-02 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
CN109153721A (en) | 2016-03-14 | 2019-01-04 | 千禧制药公司 | The method for treating or preventing graft versus host disease |
BR112018067923A2 (en) | 2016-03-15 | 2019-02-05 | Chugai Pharmaceutical Co Ltd | Cancer treatment methods using pd-1 axis binding antagonists and anti-gpc3 antibodies |
EP3430034A1 (en) | 2016-03-16 | 2019-01-23 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
WO2017162678A1 (en) | 2016-03-22 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Humanized anti-claudin-1 antibodies and uses thereof |
TW201735949A (en) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments |
EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
CN108700598A (en) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
KR20230051601A (en) | 2016-04-15 | 2023-04-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Icos ligand variant immunomodulatory proteins and uses thereof |
EP3442562B1 (en) | 2016-04-15 | 2022-09-21 | Evive Biotechnology (Shanghai) Ltd | An il-22 dimer for use in treating necrotizing enterocolitis |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
ES2850428T3 (en) | 2016-04-15 | 2021-08-30 | Hoffmann La Roche | Cancer monitoring and treatment procedures |
IL262396B2 (en) | 2016-04-15 | 2023-09-01 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
AU2017248644B2 (en) | 2016-04-15 | 2019-10-31 | Bioatla, Llc | Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
CN109071647B (en) | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | Anti-growth differentiation factor 15 antibody and application thereof |
CN109071635B (en) | 2016-05-02 | 2023-09-01 | 豪夫迈·罗氏有限公司 | Contorsbody-single stranded target conjugates |
CN109476742B (en) | 2016-05-09 | 2023-04-14 | 百时美施贵宝公司 | TL1A antibodies and uses thereof |
EP3455252B1 (en) | 2016-05-11 | 2022-02-23 | F. Hoffmann-La Roche AG | Modified anti-tenascin antibodies and methods of use |
IL262404B2 (en) | 2016-05-13 | 2024-04-01 | Bioatla Llc | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
PL3458101T3 (en) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Protac antibody conjugates and methods of use |
TW201802121A (en) | 2016-05-25 | 2018-01-16 | 諾華公司 | Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof |
CA3024508A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
JP7043425B2 (en) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | Silvestrol Antibodies-Drug Conjugates and Usage |
MA45245A (en) | 2016-06-12 | 2019-04-17 | Millennium Pharm Inc | METHOD OF TREATMENT OF INFLAMMATORY INTESTINAL DISEASE |
WO2017216724A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
CN109563160B (en) | 2016-06-24 | 2023-02-28 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
MA45715A (en) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | ANTI-HSPA5 ANTIBODIES (GRP78) AND THEIR USES |
CA3032120A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
MX2018015721A (en) | 2016-07-29 | 2019-05-27 | Chugai Pharmaceutical Co Ltd | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity. |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
EP3494142A4 (en) | 2016-08-05 | 2020-04-01 | Allakos, Inc. | Anti-siglec-7 antibodies for the treatment of cancer |
JP7250674B2 (en) | 2016-08-08 | 2023-04-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | CANCER TREATMENT AND DIAGNOSTIC METHOD |
EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
TWI739887B (en) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | Treatment cancers using a combination comprising btk inhibitors |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
US10981976B2 (en) | 2016-08-31 | 2021-04-20 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
JP6976315B2 (en) | 2016-09-19 | 2021-12-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Affinity chromatography based on complement factors |
SI3528838T1 (en) | 2016-09-23 | 2023-10-30 | F. Hoffmann-La Roche Ag | Uses of il-13 antagonists for treating atopic dermatitis |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
JP7050770B2 (en) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Method for preparing antibody drug conjugate |
KR20190072528A (en) | 2016-10-06 | 2019-06-25 | 제넨테크, 인크. | Treatment and Diagnosis Methods for Cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
MA46529A (en) | 2016-10-11 | 2019-08-21 | Agenus Inc | ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE |
JP2019535250A (en) | 2016-10-29 | 2019-12-12 | ジェネンテック, インコーポレイテッド | Anti-MIC antibody and method of use |
MA46770A (en) | 2016-11-09 | 2019-09-18 | Agenus Inc | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
JP2020500020A (en) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | Compositions, methods, and therapeutic uses related to the fusogenic protein MINION |
WO2018093821A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
JOP20190100A1 (en) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | Anti-gitr antigen-binding proteins and methods of use thereof |
KR102221364B1 (en) | 2016-11-21 | 2021-03-04 | 쿠레아브 게엠베하 | Anti-GP73 Antibody and Immunoconjugate |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
CN117820467A (en) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | anti-TAU antibodies and methods of use |
CA3044679A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
JP6992068B2 (en) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | Anti-CTLA-4 antibodies and how to use them |
TW201827076A (en) | 2016-12-12 | 2018-08-01 | 美商建南德克公司 | Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens |
EP4321219A2 (en) | 2016-12-19 | 2024-02-14 | Medimmune Limited | Antibodies against lif and uses thereof |
WO2018115960A1 (en) | 2016-12-19 | 2018-06-28 | Mosaic Biomedicals, S.L. | Antibodies against lif and uses thereof |
CA3039446A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists |
JP7139332B2 (en) | 2016-12-23 | 2022-09-20 | ノバルティス アーゲー | Factor XI Antibodies and Methods of Use |
JOP20190134A1 (en) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | Anti-neuropilin antigen-binding proteins and methods of use thereof |
MX2019007795A (en) | 2017-01-03 | 2019-08-16 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9. |
WO2018129029A1 (en) | 2017-01-04 | 2018-07-12 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
TW201833140A (en) | 2017-01-09 | 2018-09-16 | 美商莫瑞麥克製藥公司 | Anti-fgfr antibodies and methods of use |
TW201831517A (en) | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
TWI774726B (en) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | Crystalline forms of (s)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
TWI658834B (en) | 2017-01-31 | 2019-05-11 | 日商中外製藥股份有限公司 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
JOP20190187A1 (en) | 2017-02-03 | 2019-08-01 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
WO2018146594A1 (en) | 2017-02-08 | 2018-08-16 | Novartis Ag | Fgf21 mimetic antibodies and uses thereof |
MX2019009485A (en) | 2017-02-10 | 2019-11-05 | Genentech Inc | Anti-tryptase antibodies, compositions thereof, and uses thereof. |
MX2019009117A (en) | 2017-02-17 | 2019-09-13 | Bristol Myers Squibb Co | Antibodies to alpha-synuclein and uses thereof. |
WO2018157027A1 (en) | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
MX2019010295A (en) | 2017-03-01 | 2019-11-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
CN110392697A (en) | 2017-03-02 | 2019-10-29 | 国家医疗保健研究所 | There is the antibody and application thereof of specificity to NECTIN-4 |
DK3596116T3 (en) | 2017-03-16 | 2023-11-27 | Alpine Immune Sciences Inc | VARIANT IMMUNE MODULATORY PD-L1 PROTEINS AND USES THEREOF |
AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
BR112019018747A2 (en) | 2017-03-16 | 2020-05-05 | Alpine Immune Sciences Inc | variant immunomodulatory proteins of cd80 and uses thereof |
AR111249A1 (en) | 2017-03-22 | 2019-06-19 | Genentech Inc | OPTIMIZED ANTIBODY COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS |
AU2018240117A1 (en) | 2017-03-24 | 2019-09-19 | Beth Israel Deaconess Medical Center, Inc. | Methods for preventing and treating heart disease |
CN117205311A (en) | 2017-03-28 | 2023-12-12 | 基因泰克公司 | Methods of treating neurodegenerative diseases |
CN110573528B (en) | 2017-03-29 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Bispecific antigen binding molecules to costimulatory TNF receptors |
JP7205995B2 (en) | 2017-03-29 | 2023-01-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Bispecific antigen-binding molecules for co-stimulatory TNF receptors |
JOP20190203A1 (en) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | Anti-tigit antigen-binding proteins and methods of use thereof |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
RU2766234C2 (en) | 2017-04-04 | 2022-02-10 | Ф. Хоффманн-Ля Рош Аг | New bispecific antigen-binding molecules with capability of specifically binding to cd40 and fap |
CN116375876A (en) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | Bispecific antibodies that specifically bind PD1 and LAG3 |
KR102294136B1 (en) | 2017-04-05 | 2021-08-26 | 에프. 호프만-라 로슈 아게 | anti-LAG3 antibody |
TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
JP7160833B2 (en) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | anti-SIRP alpha antibody |
KR102629972B1 (en) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | Anti-CD137 antibody and methods of using the same |
AU2018251993A1 (en) | 2017-04-14 | 2019-10-24 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
JP7248588B2 (en) | 2017-04-21 | 2023-03-29 | ジェネンテック, インコーポレイテッド | Use of KLK5 antagonists for the treatment of disease |
CA3059820A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
CN110799541A (en) | 2017-04-27 | 2020-02-14 | 特沙诺有限公司 | Antibody agents against lymphocyte activation gene-3 (LAG-3) and uses thereof |
AR111651A1 (en) | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
KR20190141148A (en) | 2017-04-28 | 2019-12-23 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | How to treat pediatric disorders |
PL3618863T3 (en) | 2017-05-01 | 2023-11-06 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
US11021527B2 (en) | 2017-05-04 | 2021-06-01 | Acceleron Pharma Inc. | Transforming growth factor beta receptor type II fusion polypeptides |
BR112019022912A2 (en) | 2017-05-05 | 2020-05-26 | Allakos Inc. | METHODS AND COMPOSITIONS TO TREAT ALLERGIC EYE DISEASES |
CN111094335B (en) | 2017-05-15 | 2022-08-23 | 罗切斯特大学 | Broadly neutralizing anti-influenza monoclonal antibodies and uses thereof |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
JOP20190271A1 (en) | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
JP2020520671A (en) | 2017-05-24 | 2020-07-16 | ノバルティス アーゲー | Antibody-cytokine grafted proteins and methods of use |
CN116333129A (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antibodies comprising modified heavy chain constant regions |
JP7348072B2 (en) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | Triple combination antibody therapy |
UY37758A (en) | 2017-06-12 | 2019-01-31 | Novartis Ag | METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES |
WO2018229706A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Combination therapy for the treatment of cancer |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
JP7237853B2 (en) | 2017-06-20 | 2023-03-13 | アムジエン・インコーポレーテツド | A method of treating or ameliorating a metabolic disorder using a binding protein against the gastric inhibitory peptide receptor (GIPR) in combination with a GLP-1 agonist |
JP2020525434A (en) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | Method of treating cancer with a composition comprising amlexanox and an immunomodulator |
MX2019015057A (en) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Ror1 antibody immunoconjugates. |
KR20200020902A (en) | 2017-06-26 | 2020-02-26 | 베이진 엘티디 | Immune treatment for hepatocellular carcinoma (HCC) |
CN110785433A (en) | 2017-06-28 | 2020-02-11 | 诺华股份有限公司 | Method for preventing and treating urinary incontinence |
EP3652209A2 (en) | 2017-07-11 | 2020-05-20 | Compass Therapeutics LLC | Agonist antibodies that bind human cd137 and uses thereof |
KR20200093518A (en) | 2017-07-21 | 2020-08-05 | 제넨테크, 인크. | Methods of treatment and diagnosis for cancer |
EP3658589B1 (en) | 2017-07-26 | 2023-09-27 | Forty Seven, Inc. | Anti-sirp-alpha antibodies and related methods |
MX2020000966A (en) | 2017-07-27 | 2020-09-28 | Daiichi Sankyo Co Ltd | Anti-cd147 antibody. |
KR20200037366A (en) | 2017-08-11 | 2020-04-08 | 제넨테크, 인크. | Anti-CD8 antibodies and uses thereof |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
US11306144B2 (en) | 2017-08-25 | 2022-04-19 | Five Prime Therapeutics, Inc. | B7-H4 antibodies and methods of use thereof |
US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
CN111164208B (en) | 2017-09-29 | 2023-08-04 | 第一三共株式会社 | Antibody-pyrrolobenzodiazepine derivative conjugates |
PE20210005A1 (en) | 2017-09-29 | 2021-01-05 | Chugai Pharmaceutical Co Ltd | MULTISPECIFIC ANTIGEN BINDING MOLECULA THAT HAS SUBSTITUTE ACTIVITY OF THE COFACTOR FUNCTION OF BLOOD COAGULATION FACTOR VIII (FVIII) AND PHARMACEUTICAL FORMULATION THAT CONTAINS SUCH MOLECULA AS ACTIVE INGREDIENT |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
CA3198255A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
AU2018347521A1 (en) | 2017-10-12 | 2020-05-07 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
AU2018351000B2 (en) | 2017-10-18 | 2023-11-30 | Alpine Immune Sciences, Inc. | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods |
JP7450535B2 (en) | 2017-10-20 | 2024-03-15 | エフ. ホフマン-ラ ロシュ アーゲー | Method for generating multispecific antibodies from monospecific antibodies |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
MX2020004100A (en) | 2017-10-30 | 2020-07-24 | Hoffmann La Roche | Method for in vivo generation of multispecific antibodies from monospecific antibodies. |
WO2019089753A2 (en) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Cd137 antibodies and pd-1 antagonists and uses thereof |
JP2021502066A (en) | 2017-11-06 | 2021-01-28 | ジェネンテック, インコーポレイテッド | Cancer diagnosis and therapy |
EP3713965A1 (en) | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
CN111801334B (en) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors |
WO2019106578A2 (en) | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
WO2019110823A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
EP3728321A1 (en) | 2017-12-22 | 2020-10-28 | F. Hoffmann-La Roche AG | Use of pilra binding agents for treatment of a disease |
JP7383617B2 (en) | 2017-12-28 | 2023-11-20 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Antibodies against PD-L1 and variants thereof |
US11905327B2 (en) | 2017-12-28 | 2024-02-20 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against TIGIT |
JP7436365B2 (en) | 2017-12-29 | 2024-02-21 | エフ. ホフマン-ラ ロシュ アーゲー | Anti-VEGF antibodies and methods of use |
BR112020013236A2 (en) | 2018-01-03 | 2020-12-01 | Alpine Immune Sciences, Inc. | immunomodulatory proteins from multiple domains and methods of their use |
CA3086879A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
US20200339686A1 (en) | 2018-01-16 | 2020-10-29 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
SG11202006259SA (en) | 2018-01-26 | 2020-08-28 | Genentech Inc | Il-22 fc fusion proteins and methods of use |
HUE060435T2 (en) | 2018-01-26 | 2023-03-28 | Hoffmann La Roche | Il-22 fc compositions and methods of use |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
AU2019218959A1 (en) | 2018-02-08 | 2020-09-03 | Genentech, Inc. | Bispecific antigen-binding molecules and methods of use |
PE20211304A1 (en) | 2018-02-09 | 2021-07-20 | Genentech Inc | THERAPEUTIC AND DIAGNOSTIC METHODS FOR INFLAMMATORY DISEASES MEDIATED BY MASTOCYTES |
EP3752530A1 (en) | 2018-02-14 | 2020-12-23 | ABBA Therapeutics AG | Anti-human pd-l2 antibodies |
JP2021514354A (en) | 2018-02-21 | 2021-06-10 | ジェネンテック, インコーポレイテッド | Administration for treatment with IL-22Fc fusion protein |
AU2019225249A1 (en) | 2018-02-26 | 2020-09-17 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies |
JP2021516051A (en) | 2018-03-02 | 2021-07-01 | ファイブ プライム セラピューティクス, インコーポレイテッド | B7-H4 antibody and how to use it |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
SG11202008280TA (en) | 2018-03-05 | 2020-09-29 | Univ Saitama Medical | Pharmaceutical composition for treating or preventing heterotopic ossification |
EP3765489A1 (en) | 2018-03-13 | 2021-01-20 | F. Hoffmann-La Roche AG | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
CA3092635A1 (en) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Antibodies that bind cd39 and uses thereof |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
MX2020009296A (en) | 2018-03-15 | 2020-11-13 | Chugai Pharmaceutical Co Ltd | Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use. |
EP3768720A4 (en) | 2018-03-20 | 2022-01-05 | Wuxi Biologics Ireland Limited | Novel anti-lag-3 antibody polypeptide |
CA3092589A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
BR112020018918A2 (en) | 2018-03-22 | 2021-01-05 | Surface Oncology, Inc. | ANTI-IL-27 ANTIBODIES AND USES OF THE SAME |
WO2019183551A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
KR20230042407A (en) | 2018-03-29 | 2023-03-28 | 제넨테크, 인크. | Modulating lactogenic activity in mammalian cells |
CA3093034A1 (en) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against lag-3 and uses thereof |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
EP3552631A1 (en) | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
AU2019251289B2 (en) | 2018-04-12 | 2024-01-18 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
CA3096703A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
CN110464842B (en) | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | Formulations comprising anti-PCSK 9 antibodies and uses thereof |
WO2019222294A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
EP3794031A2 (en) | 2018-05-14 | 2021-03-24 | MedImmune Limited | Antibodies against lif and dosage forms thereof |
EP4242238A3 (en) | 2018-05-14 | 2023-12-06 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
UY38247A (en) | 2018-05-30 | 2019-12-31 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
EP3801766A1 (en) | 2018-05-31 | 2021-04-14 | Novartis AG | Hepatitis b antibodies |
PE20210320A1 (en) | 2018-06-01 | 2021-02-16 | Novartis Ag | BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM |
US20210238308A1 (en) | 2018-06-04 | 2021-08-05 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
KR20210022065A (en) | 2018-06-18 | 2021-03-02 | 메디뮨 리미티드 | Combination of LIF inhibitors and platinum-based anti-neoplastic agents for use in treating cancer |
SG11202012446UA (en) | 2018-06-23 | 2021-01-28 | Genentech Inc | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
EP3818082A1 (en) | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
EP3820904A2 (en) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
CN112673023B (en) | 2018-07-10 | 2023-09-12 | 国立大学法人神户大学 | anti-SIRP alpha antibodies |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
KR20210031722A (en) | 2018-07-11 | 2021-03-22 | 파이브 프라임 테라퓨틱스, 인크. | Antibodies that bind to VISTA at acidic pH |
TW202011991A (en) | 2018-07-18 | 2020-04-01 | 美商建南德克公司 | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
WO2020018879A1 (en) | 2018-07-20 | 2020-01-23 | Surface Oncology, Inc. | Anti-cd112r compositions and methods |
JP7401166B2 (en) | 2018-08-01 | 2023-12-19 | イムチェック セラピューティクス エスエーエス | Anti-BTN3A antibodies and their use in the treatment of cancer or infectious disorders |
TWI701041B (en) | 2018-08-01 | 2020-08-11 | 日商中外製藥股份有限公司 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
CA3106829A1 (en) | 2018-08-03 | 2020-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
WO2020033925A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
WO2020033926A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
MA50586A (en) | 2018-08-09 | 2020-09-16 | Regeneron Pharma | METHODS FOR EVALUATING THE BINDING AFFINITY OF AN ANTIBODY VARIANT TO THE NEONATAL FC RECEPTOR |
WO2020033923A1 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
AR114550A1 (en) | 2018-08-10 | 2020-09-16 | Chugai Pharmaceutical Co Ltd | ANTI-CD137 ANTIGEN BINDING MOLECULES AND THEIR USES |
TW202021618A (en) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | Anti-il1rap antibodies and methods of use thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
CA3111397A1 (en) | 2018-09-06 | 2020-03-12 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
WO2020053742A2 (en) | 2018-09-10 | 2020-03-19 | Novartis Ag | Anti-hla-hbv peptide antibodies |
AU2019339469A1 (en) | 2018-09-13 | 2021-03-11 | Immune-Onc Therapeutics, Inc. | Novel LILRB4 antibodies and uses thereof |
CN112955747A (en) | 2018-09-19 | 2021-06-11 | 豪夫迈·罗氏有限公司 | Methods for treatment and diagnosis of bladder cancer |
WO2020061376A2 (en) | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
ES2955032T3 (en) | 2018-09-21 | 2023-11-28 | Hoffmann La Roche | Diagnostic methods for triple negative breast cancer |
JP2022502088A (en) | 2018-09-27 | 2022-01-11 | エクシリオ デベロップメント, インコーポレイテッド | Masked cytokine polypeptide |
EP3861025A1 (en) | 2018-10-01 | 2021-08-11 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules with trivalent binding to cd40 |
MA53806A (en) | 2018-10-01 | 2022-01-05 | Hoffmann La Roche | BISPECIFIC ANTIGEN-BINDING MOLECULES COMPRISING AN ANTI-FAP 212 CLONE |
CN113164780A (en) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | anti-LAP antibody variants and uses thereof |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
MX2021004348A (en) | 2018-10-18 | 2021-05-28 | Genentech Inc | Diagnostic and therapeutic methods for sarcomatoid kidney cancer. |
US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
AU2019375413A1 (en) | 2018-11-05 | 2021-05-27 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
KR20210088571A (en) | 2018-11-07 | 2021-07-14 | 다이이찌 산쿄 가부시키가이샤 | Method for improving blood kinetics of peptides |
CA3119968A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
TWI779253B (en) | 2018-11-27 | 2022-10-01 | 大陸商信達生物製藥(蘇州)有限公司 | ANTI-IL-23p19 ANTIBODY AND USE THEREOF |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
JP2022510276A (en) | 2018-11-30 | 2022-01-26 | アルパイン イミューン サイエンシズ インコーポレイテッド | CD86 variant immunomodulatory protein and its use |
EP4198057A1 (en) | 2018-12-05 | 2023-06-21 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for cancer immunotherapy |
WO2020117257A1 (en) | 2018-12-06 | 2020-06-11 | Genentech, Inc. | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
CN113227119A (en) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | Photocrosslinked peptides for site-specific conjugation to Fc-containing proteins |
CR20210310A (en) | 2018-12-14 | 2021-11-24 | Boehringer Ingelheim Io Canada Inc | Anti-periostin antibodies and uses thereof |
WO2020128863A1 (en) | 2018-12-19 | 2020-06-25 | Novartis Ag | Anti-tnf-alpha antibodies |
AR117327A1 (en) | 2018-12-20 | 2021-07-28 | 23Andme Inc | ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM |
AR117453A1 (en) | 2018-12-20 | 2021-08-04 | Genentech Inc | CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM |
AU2019405782A1 (en) | 2018-12-21 | 2021-06-17 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
PE20211296A1 (en) | 2018-12-21 | 2021-07-20 | Novartis Ag | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF |
AU2019403313A1 (en) | 2018-12-21 | 2021-07-15 | Genentech, Inc. | Methods of producing polypeptides using a cell line resistant to apoptosis |
MX2021007421A (en) | 2018-12-21 | 2021-08-05 | Hoffmann La Roche | Antibody that binds to vegf and il-1beta and methods of use. |
JP2022516881A (en) | 2018-12-26 | 2022-03-03 | キシリオ ディベロップメント インコーポレイテッド | Anti-CTLA4 antibody and how to use it |
CN113272327A (en) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | Anti-rabbit CD19 antibodies and methods of use thereof |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
JP2022518399A (en) | 2019-01-14 | 2022-03-15 | ジェネンテック, インコーポレイテッド | How to Treat Cancer with PD-1 Axial Binding Antagonists and RNA Vaccines |
CA3127072A1 (en) | 2019-01-16 | 2020-07-23 | Compass Therapeutics Llc | Formulations of antibodies that bind human cd137 and uses thereof |
CN113396162A (en) | 2019-01-22 | 2021-09-14 | 百时美施贵宝公司 | Antibodies against IL-7R alpha subunit and uses thereof |
AU2020211974A1 (en) | 2019-01-22 | 2021-08-05 | Genentech, Inc. | Immunoglobulin a antibodies and methods of production and use |
EP3914615A1 (en) | 2019-01-23 | 2021-12-01 | F. Hoffmann-La Roche AG | Methods of producing multimeric proteins in eukaryotic host cells |
JPWO2020153467A1 (en) | 2019-01-24 | 2021-12-02 | 中外製薬株式会社 | New cancer antigens and antibodies against those antigens |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
JP2022521773A (en) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody |
KR20210138588A (en) | 2019-03-08 | 2021-11-19 | 제넨테크, 인크. | Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles |
JP2022524074A (en) | 2019-03-14 | 2022-04-27 | ジェネンテック, インコーポレイテッド | Treatment of cancer with HER2xCD3 bispecific antibodies in combination with anti-HER2 MAB |
KR20210143237A (en) | 2019-03-25 | 2021-11-26 | 다이이찌 산쿄 가부시키가이샤 | Antibody-pyrrolobenzodiazepine derivative conjugate |
EP3949988A4 (en) | 2019-03-27 | 2022-11-16 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
MX2021012160A (en) | 2019-04-08 | 2022-01-06 | Biogen Ma Inc | Anti-integrin antibodies and uses thereof. |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
SG11202111033VA (en) | 2019-04-17 | 2021-11-29 | Alpine Immune Sciences Inc | Methods and uses of variant icos ligand (icosl) fusion proteins |
KR20220002967A (en) | 2019-04-19 | 2022-01-07 | 제넨테크, 인크. | Anti-MERTK antibodies and methods of use thereof |
MX2021012506A (en) | 2019-04-19 | 2022-01-24 | Chugai Pharmaceutical Co Ltd | Chimeric receptor recognizing modification site of antibody. |
CN114269376A (en) | 2019-05-03 | 2022-04-01 | 豪夫迈·罗氏有限公司 | Methods of treating cancer with anti-PD-L1 antibodies |
CN114206340A (en) | 2019-05-14 | 2022-03-18 | 豪夫迈·罗氏有限公司 | Methods of treating follicular lymphoma using anti-CD 79B immunoconjugates |
BR112021022666A2 (en) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Separation fractions and their methods and use |
CA3140063A1 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
PE20220218A1 (en) | 2019-05-20 | 2022-02-02 | Novartis Ag | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
EP3972634A2 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Trispecific binding molecules against bcma and uses thereof |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2020236792A1 (en) | 2019-05-21 | 2020-11-26 | Novartis Ag | Cd19 binding molecules and uses thereof |
KR20220012270A (en) | 2019-05-23 | 2022-02-03 | 에이씨 이뮨 에스.에이. | Anti-TDP-43 binding molecules and uses thereof |
MA56102A (en) | 2019-06-07 | 2022-04-13 | Argenx Bvba | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION |
CA3141561A1 (en) | 2019-06-12 | 2020-12-17 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
CN114245807A (en) | 2019-06-25 | 2022-03-25 | 吉利德科学公司 | FLT3L-FC fusion proteins and methods of use |
EP3990492A1 (en) | 2019-06-27 | 2022-05-04 | F. Hoffmann-La Roche AG | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
AR119382A1 (en) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | PRE-TARGETING ANTIBODIES AND METHODS OF USE |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
EP3999541A1 (en) | 2019-07-15 | 2022-05-25 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
JP2022541200A (en) | 2019-07-16 | 2022-09-22 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | Antibody having specificity for CD38 and use thereof |
JP2022542863A (en) | 2019-07-24 | 2022-10-07 | ハー・ルンドベック・アクチエゼルスカベット | Anti-mGluR5 antibody and uses thereof |
WO2021020282A1 (en) | 2019-07-26 | 2021-02-04 | 学校法人埼玉医科大学 | Antibody recognizing extracellular region of alk2/acvr1 |
KR20220041881A (en) | 2019-07-29 | 2022-04-01 | 컴퓨젠 엘티디. | Anti-PVRIG antibody formulations and uses thereof |
EP4003408A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
KR20240033090A (en) | 2019-07-31 | 2024-03-12 | 에프. 호프만-라 로슈 아게 | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
WO2021024209A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Inc. | Antibodies that bind to pathological tau species and uses thereof |
AU2020329217A1 (en) | 2019-08-12 | 2022-07-28 | Aptevo Research And Development Llc | 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40 |
CR20220076A (en) | 2019-08-30 | 2022-06-24 | Agenus Inc | Anti-cd96 antibodies and methods of use thereof |
JP2022547577A (en) | 2019-09-12 | 2022-11-14 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating lupus nephritis |
JP2022548484A (en) | 2019-09-16 | 2022-11-21 | サーフィス オンコロジー インコーポレイテッド | Anti-CD39 Antibody Compositions and Methods |
MX2022003212A (en) | 2019-09-18 | 2022-04-25 | Genentech Inc | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use. |
JP2022548881A (en) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
US20230192860A1 (en) | 2019-09-19 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies Binding to Vista at Acidic pH |
CR20220149A (en) | 2019-09-20 | 2022-05-23 | Genentech Inc | Dosing for anti-tryptase antibodies |
TW202128752A (en) | 2019-09-25 | 2021-08-01 | 美商表面腫瘤學公司 | Anti-il-27 antibodies and uses thereof |
CR20220127A (en) | 2019-09-27 | 2022-05-27 | Genentech Inc | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20220372161A1 (en) | 2019-10-08 | 2022-11-24 | Nectin Therapeutics Ltd. | Antibodies against the poliovirus receptor (pvr) and uses thereof |
PE20221039A1 (en) | 2019-10-18 | 2022-06-17 | Genentech Inc | METHODS FOR USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA |
WO2021080682A1 (en) | 2019-10-24 | 2021-04-29 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human cd161 and uses thereof |
EP4054632A1 (en) | 2019-11-04 | 2022-09-14 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
US20220389103A1 (en) | 2019-11-06 | 2022-12-08 | Genentech, Inc. | Diagnostic and therapeutic methods for treatment of hematologic cancers |
CN114929741A (en) | 2019-12-04 | 2022-08-19 | 免疫医疗有限公司 | Antibodies against LIF and uses thereof |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
CR20230210A (en) | 2019-12-13 | 2023-06-14 | Genentech Inc | Anti-ly6g6d antibodies and methods of use |
CN113045655A (en) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
AU2019479791A1 (en) | 2019-12-27 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
MX2022008341A (en) | 2020-01-06 | 2022-08-10 | Vaccinex Inc | Anti-ccr8 antibodies and uses thereof. |
EP4087875A1 (en) | 2020-01-08 | 2022-11-16 | Argenx BV | Methods for treating pemphigus disorders |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
JP2023512654A (en) | 2020-01-31 | 2023-03-28 | ジェネンテック, インコーポレイテッド | Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
WO2021173844A1 (en) | 2020-02-26 | 2021-09-02 | Biograph 55, Inc. | C19 c38 bispecific antibodies |
CN115066440A (en) | 2020-02-28 | 2022-09-16 | 上海复宏汉霖生物技术股份有限公司 | anti-CD 137 constructs and uses thereof |
WO2021170071A1 (en) | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
WO2021175954A1 (en) | 2020-03-04 | 2021-09-10 | Imcheck Therapeutics Sas | Antibodies having specificity for btnl8 and uses thereof |
US20230235073A1 (en) | 2020-03-06 | 2023-07-27 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
US20230330248A1 (en) | 2020-03-06 | 2023-10-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
CN115485295A (en) | 2020-03-10 | 2022-12-16 | 麻省理工学院 | Compositions and methods for immunotherapy of NPM1 c-positive cancers |
CN115605507A (en) | 2020-03-13 | 2023-01-13 | 基因泰克公司(Us) | Anti-interleukin-33 antibodies and uses thereof |
KR20220154140A (en) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | PVRIG binding proteins and their medical uses |
CN117551194A (en) | 2020-03-19 | 2024-02-13 | 基因泰克公司 | Isotype selective anti-TGF-beta antibodies and methods of use |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
BR112022018847A2 (en) | 2020-03-24 | 2022-11-22 | Genentech Inc | ANTIBODIES, NUCLEIC ACID, HOST CELL, CONJUGATES, PHARMACEUTICAL COMPOSITION, LONG-ACTION DELIVERY DEVICE FOR OCULAR DELIVERY, METHOD FOR TREAT A DISORDER AND USE OF THE ANTIBODY |
CN115315512A (en) | 2020-03-26 | 2022-11-08 | 基因泰克公司 | Modified mammalian cells with reduced host cell proteins |
WO2021195513A1 (en) | 2020-03-27 | 2021-09-30 | Novartis Ag | Bispecific combination therapy for treating proliferative diseases and autoimmune disorders |
CN115397850A (en) | 2020-03-30 | 2022-11-25 | 豪夫迈·罗氏有限公司 | Antibodies that bind to VEGF and PDGF-B and methods of use thereof |
AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
WO2021202235A1 (en) | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
CN115698717A (en) | 2020-04-03 | 2023-02-03 | 基因泰克公司 | Methods of treatment and diagnosis of cancer |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
US20230265204A1 (en) | 2020-04-24 | 2023-08-24 | Hoffmann-La Roche Inc. | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
IL297541A (en) | 2020-04-24 | 2022-12-01 | Genentech Inc | Methods of using anti-cd79b immunoconjugates |
JP2023523450A (en) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | Methods and compositions for non-small cell lung cancer immunotherapy |
SG11202112792WA (en) | 2020-04-28 | 2021-12-30 | Univ Rockefeller | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
CN115996951A (en) | 2020-04-30 | 2023-04-21 | 赛罗帕私人有限公司 | anti-CD 103 antibodies |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
IL297830A (en) | 2020-05-03 | 2023-01-01 | Levena Suzhou Biopharma Co Ltd | Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same |
AU2021267276A1 (en) | 2020-05-08 | 2022-12-15 | Alpine Immune Sciences, Inc. | April and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
JP2023525053A (en) | 2020-05-12 | 2023-06-14 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | A new method to treat cutaneous T-cell lymphoma and TFH-derived lymphoma |
AR122111A1 (en) | 2020-05-17 | 2022-08-17 | Astrazeneca Uk Ltd | ANTIBODIES AGAINST SARS-CoV-2 AND METHODS OF SELECTION AND USE OF THEM |
EP4139002A2 (en) | 2020-05-22 | 2023-03-01 | Formycon AG | Ace2-fc fusion proteins and uses thereof |
WO2021238886A1 (en) | 2020-05-27 | 2021-12-02 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
US11787861B2 (en) | 2020-05-29 | 2023-10-17 | 23Andme, Inc. | Anti-CD200R1 antibodies and methods of use thereof |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
TW202210515A (en) | 2020-06-02 | 2022-03-16 | 美商當康生物科技有限公司 | Anti-cd93 constructs and uses thereof |
AU2021288916A1 (en) | 2020-06-08 | 2022-11-24 | F.Hoffmann-La Roche Ag | Anti-HBV antibodies and methods of use |
WO2021252977A1 (en) | 2020-06-12 | 2021-12-16 | Genentech, Inc. | Methods and compositions for cancer immunotherapy |
CA3181820A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
CA3181672A1 (en) | 2020-06-18 | 2021-12-23 | Shi Li | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
CN116234824A (en) | 2020-06-22 | 2023-06-06 | 阿尔米雷尔有限公司 | anti-IL-36 antibodies and methods of use thereof |
WO2021259199A1 (en) | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | Anti-cd73 antibody and use thereof |
WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
BR112022026575A2 (en) | 2020-06-25 | 2023-01-17 | Merck Sharp & Dohme Llc | HIGH AFFINITY ANTIBODIES TARGETING PHOSPHORYLATED TAU IN SERINE 413 |
US20230272116A1 (en) | 2020-07-10 | 2023-08-31 | Hoffmann-La Roche Inc. | Antibodies which bind to cancer cells and target radionuclides to said cells |
AU2021308653A1 (en) | 2020-07-17 | 2023-02-16 | Genentech, Inc. | Anti-Notch2 antibodies and methods of use |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
IL300121A (en) | 2020-07-29 | 2023-03-01 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
JP2023536602A (en) | 2020-08-03 | 2023-08-28 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for lymphoma |
EP4193153A1 (en) | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
CN116234577A (en) | 2020-08-10 | 2023-06-06 | 阿斯利康(英国)有限公司 | SARS-COV-2 antibodies for the treatment and prevention of COVID-19 |
PE20231105A1 (en) | 2020-08-25 | 2023-07-19 | Gilead Sciences Inc | MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AGAINST HIV AND METHODS OF USE |
EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
JP2023539201A (en) | 2020-08-28 | 2023-09-13 | ジェネンテック, インコーポレイテッド | CRISPR/Cas9 multiplex knockout of host cell proteins |
PE20230986A1 (en) | 2020-09-04 | 2023-06-21 | Hoffmann La Roche | ANTIBODY THAT BINDS VEGF-A AND ANG2, AND METHODS OF USE |
EP4211165A1 (en) | 2020-09-14 | 2023-07-19 | Ichnos Sciences SA | Antibodies that bind to il1rap and uses thereof |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202233671A (en) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Peg-conjugated anti-mertk antibodies and methods of use |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
WO2022090801A2 (en) | 2020-10-26 | 2022-05-05 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
MX2023004933A (en) | 2020-10-29 | 2023-06-06 | Formycon Ag | Ace2 fusion proteins and uses thereof. |
WO2022098648A2 (en) | 2020-11-04 | 2022-05-12 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
KR20230095119A (en) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies |
CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
US11919945B2 (en) | 2020-11-04 | 2024-03-05 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
CN116472288A (en) | 2020-11-06 | 2023-07-21 | 诺华股份有限公司 | Antibody Fc variants |
IL302412A (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
CN116916919A (en) | 2020-11-11 | 2023-10-20 | 第一三共株式会社 | Combination of antibody-drug conjugates and anti-SIRPalpha antibodies |
EP4251208A1 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
CR20230283A (en) | 2020-11-24 | 2023-07-27 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
MX2023006426A (en) | 2020-12-01 | 2023-07-17 | Aptevo Res And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies. |
US20240052042A1 (en) | 2020-12-14 | 2024-02-15 | Novartis Ag | Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof |
EP4263609A1 (en) | 2020-12-17 | 2023-10-25 | F. Hoffmann-La Roche AG | Anti-hla-g antibodies and use thereof |
JP2023554456A (en) | 2020-12-18 | 2023-12-27 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | Molecule that specifically binds to respiratory syncytial virus |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
WO2022135467A1 (en) | 2020-12-23 | 2022-06-30 | 信达生物制药(苏州)有限公司 | Anti-b7-h3 antibody and uses thereof |
MX2023007846A (en) | 2021-01-06 | 2023-07-07 | F Hoffmann La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody. |
CA3206466A1 (en) | 2021-01-12 | 2022-07-21 | Christian Klein | Split antibodies which bind to cancer cells and target radionuclides to said cells |
AU2022207624A1 (en) | 2021-01-13 | 2023-07-13 | F. Hoffmann-La Roche Ag | Combination therapy |
EP4277926A1 (en) | 2021-01-15 | 2023-11-22 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
US20240076373A1 (en) | 2021-01-28 | 2024-03-07 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
EP4284516A1 (en) | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
TW202241454A (en) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | Novel method for producing antibody-immunostimulator conjugate |
JP2024509695A (en) | 2021-02-03 | 2024-03-05 | ジェネンテック, インコーポレイテッド | Multispecific binding proteolysis platform and methods of use |
PE20231680A1 (en) | 2021-02-17 | 2023-10-19 | Dr Falk Pharma Gmbh | ANTI-CD30L ANTIBODIES AND USES OF THESE |
WO2022187272A1 (en) | 2021-03-01 | 2022-09-09 | Xilio Development, Inc. | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
US20220306743A1 (en) | 2021-03-01 | 2022-09-29 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
CA3210069A1 (en) | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
CA3205815A1 (en) | 2021-03-03 | 2022-09-09 | Alwin REITER | Formulations of ace2 fc fusion proteins |
EP4301472A1 (en) | 2021-03-05 | 2024-01-10 | Dynamicure Biotechnology LLC | Anti-vista constructs and uses thereof |
KR20230148226A (en) | 2021-03-10 | 2023-10-24 | 이뮤노웨이크 인크. | Immunomodulatory Molecules and Their Uses |
WO2022192647A1 (en) | 2021-03-12 | 2022-09-15 | Genentech, Inc. | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
TW202300521A (en) | 2021-03-15 | 2023-01-01 | 美商建南德克公司 | Compositions and methods of treating lupus nephritis |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
JP2024511424A (en) | 2021-03-25 | 2024-03-13 | ダイナミキュア バイオテクノロジー エルエルシー | Anti-IGFBP7 construct and its use |
TW202304508A (en) | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
BR112023021475A2 (en) | 2021-04-16 | 2023-12-19 | Novartis Ag | ANTIBODY-DRUG CONJUGATES AND METHODS FOR PRODUCING THEM |
CA3215965A1 (en) | 2021-04-19 | 2022-10-27 | Amy Shen | Modified mammalian cells |
EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
JP2024516970A (en) | 2021-05-07 | 2024-04-18 | サーフィス オンコロジー, エルエルシー | Anti-IL-27 antibodies and uses thereof |
KR20240019124A (en) | 2021-05-07 | 2024-02-14 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Administration and treatment method of TACI-FC fusion immunoregulatory protein |
EP4337266A1 (en) | 2021-05-12 | 2024-03-20 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
TW202306993A (en) | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Agonists of trem2 |
TW202313094A (en) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | Methods of using flt3l-fc fusion proteins |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
EP4155321A1 (en) | 2021-06-04 | 2023-03-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ddr2 antibodies and uses thereof |
AU2022293999A1 (en) | 2021-06-14 | 2023-11-30 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
EP4355785A1 (en) | 2021-06-17 | 2024-04-24 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022269451A1 (en) | 2021-06-22 | 2022-12-29 | Novartis Ag | Bispecific antibodies for use in treatment of hidradenitis suppurativa |
CN117616123A (en) | 2021-06-25 | 2024-02-27 | 中外制药株式会社 | anti-CTLA-4 antibodies |
AR126236A1 (en) | 2021-06-25 | 2023-10-04 | Chugai Pharmaceutical Co Ltd | USE OF THE ANTI-CTLA-4 ANTIBODY |
WO2023275621A1 (en) | 2021-07-01 | 2023-01-05 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
AU2022302170A1 (en) | 2021-07-02 | 2023-12-21 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
TW202317633A (en) | 2021-07-08 | 2023-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing tnfr2 and uses thereof |
US20230048743A1 (en) | 2021-07-12 | 2023-02-16 | Genentech Inc. | Structures for Reducing Antibody-Lipase Binding |
AU2022310847A1 (en) | 2021-07-14 | 2024-01-25 | Genentech, Inc. | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use |
CN115812082A (en) | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | Antibody specifically recognizing CD40 and application thereof |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
AU2022315528A1 (en) | 2021-07-22 | 2023-10-19 | F. Hoffmann-La Roche Ag | Heterodimeric fc domain antibodies |
CA3224180A1 (en) | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
CA3231174A1 (en) | 2021-08-02 | 2023-02-09 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-cd79bxcd3 bispecific antibody and use thereof |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
US20230099756A1 (en) | 2021-08-07 | 2023-03-30 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
CN117858905A (en) | 2021-08-19 | 2024-04-09 | 豪夫迈·罗氏有限公司 | Multivalent anti-variant FC region antibodies and methods of use |
TW202328177A (en) | 2021-08-27 | 2023-07-16 | 美商建南德克公司 | Methods of treating tau pathologies |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
CA3232806A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
WO2023064958A1 (en) | 2021-10-15 | 2023-04-20 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies |
WO2023081818A1 (en) | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
TW202337494A (en) | 2021-11-16 | 2023-10-01 | 美商建南德克公司 | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
TW202334202A (en) | 2021-11-16 | 2023-09-01 | 瑞士商Ac免疫有限公司 | Novel molecules for therapy and diagnosis |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
WO2023114829A1 (en) | 2021-12-15 | 2023-06-22 | Genentech, Inc. | Stabilized il-18 polypeptides and uses thereof |
WO2023117834A1 (en) | 2021-12-20 | 2023-06-29 | F. Hoffmann-La Roche Ag | Agonistic ltbr antibodies and bispecific antibodies comprising them |
US20230227545A1 (en) | 2022-01-07 | 2023-07-20 | Johnson & Johnson Enterprise Innovation Inc. | Materials and methods of il-1beta binding proteins |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023168352A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
US20240103010A1 (en) | 2022-03-18 | 2024-03-28 | Compugen Ltd. | Pvrl2 and/or pvrig as biomarkers for treatment |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023186756A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Interferon gamma variants and antigen binding molecules comprising these |
WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
TW202400638A (en) | 2022-05-10 | 2024-01-01 | 法商感應檢查療法公司 | Anti-btn3a antibodies for use in methods of treating gastro-intestinal inflammatory disorders |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
TW202402810A (en) | 2022-05-11 | 2024-01-16 | 瑞士商赫孚孟拉羅股份公司 | Antibody that binds to vegf-a and il6 and methods of use |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
US20230406942A1 (en) | 2022-06-10 | 2023-12-21 | Horizon Therapeutics Ireland Dac | Igf1r antibodies |
WO2023242372A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn/hsa binding molecules and methods of use |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
US20240025978A1 (en) | 2022-06-24 | 2024-01-25 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
WO2024026496A1 (en) | 2022-07-28 | 2024-02-01 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
-
1994
- 1994-06-15 CA CA 2163345 patent/CA2163345A1/en not_active Abandoned
- 1994-06-15 JP JP7501518A patent/JPH08511420A/en active Pending
- 1994-06-15 EP EP94917750A patent/EP0714409A1/en not_active Withdrawn
- 1994-06-15 AU AU69341/94A patent/AU691811B2/en not_active Ceased
- 1994-06-15 WO PCT/GB1994/001290 patent/WO1994029351A2/en not_active Application Discontinuation
Non-Patent Citations (8)
Title |
---|
ALEGRE M.-L. ET AL.: "Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody", JOURNAL OF IMMUNOLOGY, vol. 148, June 1992 (1992-06-01), BALTIMORE US, pages 3461 - 3468 * |
CHAPPEL M. S. ET AL.: "Identification of the Fcgamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 88, October 1991 (1991-10-01), WASHINGTON US, pages 9036 - 9040 * |
DUNCAN A.R. ET AL.: "The binding site for C1q on IgG", NATURE, vol. 332, 1988, LONDON GB, pages 738 - 740 * |
GREENWOOD J. ET AL.: "Structural motifs involved in human IgG antibody effector functions", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 23, 1993, pages 1098 - 1104 * |
JOLIFFE L. K.: "Humanized antibodies: enhancing therapeutic utility through antibody engineering", INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 10, June 1993 (1993-06-01), LONDON GB, pages 241 - 250 * |
LAMPSON L. A. ET AL.: "Two populationS of Ia-like molecules on a human B cell line", JOURNAL OF IMMUNOLOGY, vol. 125, 1980, BALTIMORE US, pages 293 - 299 * |
NOSE M. ET AL.: "Biological significance of carbohydrate chains on monoclonal antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 80, 1983, WASHINGTON US, pages 6632 - 6636 * |
TAO M.-H. ET AL.: "The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal seqence of the Ch2 domain", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 173, no. 4, April 1991 (1991-04-01), pages 1025 - 1028 * |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8986686B2 (en) | 2002-06-14 | 2015-03-24 | Medimmune, Llc | Stabilized liquid anti-RSV antibody formulations |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US8779100B2 (en) | 2004-09-03 | 2014-07-15 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8957187B2 (en) | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US9375466B2 (en) | 2007-09-04 | 2016-06-28 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9107862B2 (en) | 2007-09-04 | 2015-08-18 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9555087B2 (en) | 2007-09-04 | 2017-01-31 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US9469692B2 (en) | 2008-04-02 | 2016-10-18 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US8410250B2 (en) | 2009-03-25 | 2013-04-02 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US8710189B2 (en) | 2009-03-25 | 2014-04-29 | Genentech, Inc. | Anti-FGFR3 antibodies and methods using same |
US9283274B2 (en) | 2009-10-06 | 2016-03-15 | Medimmune Limited | RSV specific binding molecule |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US9133273B2 (en) | 2010-11-19 | 2015-09-15 | Eisai R&D Management Co., Ltd. | Nucleic acids encoding neutralizing anti-CCL20 antibodies |
US8969526B2 (en) | 2011-03-29 | 2015-03-03 | Roche Glycart Ag | Antibody Fc variants |
US9428574B2 (en) | 2011-06-30 | 2016-08-30 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US9266961B2 (en) | 2012-06-15 | 2016-02-23 | Genentech, Inc. | Anti-PCSK9 antibodies, formulations, dosing, and methods of use |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
EP4342529A2 (en) | 2015-12-18 | 2024-03-27 | Chugai Seiyaku Kabushiki Kaisha | Anti-c5 antibodies and methods of use |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JPH08511420A (en) | 1996-12-03 |
AU691811B2 (en) | 1998-05-28 |
AU6934194A (en) | 1995-01-03 |
WO1994029351A2 (en) | 1994-12-22 |
EP0714409A1 (en) | 1996-06-05 |
CA2163345A1 (en) | 1994-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994029351A3 (en) | Antibodies | |
AU4472793A (en) | Methods for diagnosis and therapy using defined regions of the T cell antigen receptor | |
AU637202B2 (en) | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent | |
IL90990A0 (en) | Pharmaceutical and diagnostic compositions containing monoclonal antibodies reactive with cachectin and a cell for the production thereof | |
AU588806B2 (en) | Drug, and methods of preparing and using it for treatment of tumors | |
WO1998022136A3 (en) | Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies | |
DE93619T1 (en) | PLASMINOGENACTIVATOR FOR HUMAN TISSUE, PHARMACEUTICAL COMPOSITIONS CONTAINING THIS ACTIVATOR, METHOD FOR PRODUCING THE ACTIVATOR AND DNA AND TRANSFORMED CELL INTERMEDIATE PRODUCTS THEREFOR. | |
DE2963977D1 (en) | Antigen preparation, process for producing it and pharmacological or dental preparations containing the antigen preparation or antibodies thereto | |
CA2212058A1 (en) | Preparation and use of a specific gaba-a.alpha.5 receptor ligand for treatment of alzheimer's disease | |
WO1997008318A3 (en) | Compounds and methods for treatment and diagnosis of prostate cancer | |
AU6785987A (en) | Selecting and testing antibodies for cancer therapy | |
SI0771788T1 (en) | Substituted sulphonimidamides, method for their preparation, their use as medicament or diagnostic and medicament containing them | |
EP0147146A3 (en) | Enhancement of transdermal drug delivery | |
AU1347688A (en) | Viral antigen, process for its production, and application in diagnosis and therapy (vaccine) | |
IL81370A (en) | Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions | |
EP0200169A3 (en) | Pharmaceutical composition for cure and prevention of cardiovascular disease and method of preparing the same | |
ES8704082A1 (en) | Tumour therapeutic agent and process for its preparation. | |
MY113431A (en) | Substituted benzenesulfonylureas and -thioureas, process for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
AU591901B2 (en) | Process for the in vitro immunization of human splenocytes against tumor associated antigens | |
DE3061405D1 (en) | Process for the preparation of hydrocarbons, and hydrocarbons so prepared | |
IE860227L (en) | Monoclonal anti-alpha-amylase antibody | |
AU569354B2 (en) | (-)-1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane | |
AU3806285A (en) | Hydantoin derivatives, process for producing the same and medicine containing the same. | |
JPS5615215A (en) | Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel | |
AU4081085A (en) | Process for preparing glycosidic linkage related antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2163345 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994917750 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 564250 Country of ref document: US Date of ref document: 19960212 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1994917750 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994917750 Country of ref document: EP |